DOR/ISL

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ImmunodeficiencyAntiretroviral Treatment

53 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

1

Fuzeon

CConrado Roberto Hoffmann Filho

Approved

72

Adenocard

Astellas

Approved

—3

Busulfex

Akero Therapeutics

Approved

14

Viramune

Boehringer Ingelheim

Approved

15

Rayos

RRoxane Laboratories

Approved

16

Cabenuva

GSK

Phase 3

57

Edurant Ped

WWim Janssens

Phase 3

88

B/F/TAF

Gilead

Phase 3

79

Immunoglobulin

Sanofi

Phase 3

210

Cellcept

Roche

Phase 2

3Show 39 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunodeficiency7 trials

Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

Completed·Merck & Co.·Phase 2·NCT04295772·42 enrolled

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

Active, not recruiting·Merck & Co.·Phase 3·NCT05766501·641 enrolled

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

Completed·Merck & Co.·Phase 3·NCT04223791·643 enrolled

Show 4 more trials

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

Completed·Merck & Co.·Phase 3·NCT04233879·599 enrolled

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

Active, not recruiting·Merck & Co.·Phase 3·NCT05630755·514 enrolled

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

Completed·Merck & Co.·Phase 3·NCT04233216·35 enrolled

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

Active, not recruiting·Merck & Co.·Phase 3·NCT05631093·553 enrolled

Antiretroviral Treatment1 trial

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

Active, not recruiting·Merck & Co.·Phase 3·NCT05705349·537 enrolled

Female1 trial

A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)

Completed·Merck & Co.·Phase 1·NCT07086079·12 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

Completed·Merck & Co.·Phase 3·NCT04223778·672 enrolled

Details

Drug Info

Related News